Bristol-Myers Squibb Company operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Bristol-Myers Squibb Company with three other companies in this sector in UNITED STATES : Abbvie Inc (2020 sales of $45.80 billion of which 100% was pharmaceutical products), Merck & Co. , Inc. ($47.99 billion of which 90% was Merck Pharmaceutical), and Pfizer Inc. ($41.91 billion of which 26% was Oncology).

Sales Analysis. During the second quarter of 2021, sales at Bristol-Myers Squibb Company totalled $11.70 billion. This is an increase of 15.5% from the $10.13 billion in sales at the company during the second quarter of 2020. During the first two quarters of 2021, sales totalled $22.78 billion, which is 8.9% higher than through the first two quarters of 2020. During the previous 26 quarters, sales at Bristol-Myers Squibb Company have increased compared with the same quarter in the previous year. There appears to be at least some degree of seasonality in the sales at Bristol-Myers Squibb Company: during 8 of the previous 9 years, sales were highest during the fourth quarter. The exception to this was during 2012, when the first quarter was the best quarter, accounting for 30% of sales (during that same year, the fourth quarter accounted for 24% of sales). During the year ended December of 2020, sales at Bristol-Myers Squibb Company were $42.52 billion. This is an increase of 62.6% versus 2019, when the company's sales were $26.15 billion. This was the fifth consecutive year of sales increases at Bristol-Myers Squibb Company (and since 2015, sales have increased a total of 157%). Sales of Prioritized Brands-Revlimid saw an increase that was more than double the company's growth rate: sales were up 831.9% in 2020, from $1.30 billion to $12.11 billion. Not all segments of Bristol-Myers Squibb Company experienced an increase in sales in 2020: sales of Other Brands fell 21.4% to $1.32 billion. Bristol-Myers Squibb Company also experienced decreases in sales in Prioritized Brands-Opdivo (down 2.9% to $6.99 billion) .